Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Mansur, RB; Zugman, A; Ahmed, J; Cha, DS; Subramaniapillai, M; Lee, Y; Lovshin, J; Lee, JG; Lee, JH; Drobinin, V; Newport, J; Brietzke, E; Reininghaus, EZ; Sim, K; Vinberg, M; Rasgon, N; Hajek, T; McIntyre, RS.
Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders.
Eur Neuropsychopharmacol. 2017; 27(11):1153-1162
Doi: 10.1016/j.euroneuro.2017.08.433
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Reininghaus Eva
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Cognitive deficits are a core feature across psychiatric disorders. Emerging evidence indicates that metabolic pathways are highly relevant for the substrates and phenomenology of the cognitive domain. Herein, we aimed to determine the effects of liraglutide, a GLP-1R agonist, on brain structural/volumetric parameters in adults with a mood disorder. This is the secondary analysis of a 4-week, pilot, proof-of-concept, open-label study. Participants (N=19) exhibiting impairments in executive function with either major depressive disorder (MDD) or bipolar disorder (BD) were recruited. Liraglutide 1.8mg/day was added as an adjunct to existing pharmacotherapy. Structural magnetic resonance imaging (MRI) scanning was obtained at baseline and endpoint. Results showed that at endpoint there was significant weight loss (mean: 3.15%; p<0.001). Changes in frontal and striatal volumes were significantly correlated with changes in body mass index (BMI), indicating the weight loss was associated with volume increase in most regions (e.g. r=-0.561, p=0.042 in the left superior frontal area). After adjusting for intracranial volume, age, gender, and BMI, we observed significant changes from baseline to endpoint in multiple regions (e.g. RR: 1.011, p=0.049 in the left rostral middle frontal area). Changes in regional volumes were associated with improvement in executive function (e.g. r=0.698, p=0.003 for the right superior frontal area). Adjunctive liraglutide results in clinically significant weight loss, with corresponding improvement in cognitive function; changes in cognitive function were partially moderated by changes in brain morphometry, underscoring the interrelationship between weight and brain structure/function. Copyright © 2017 Elsevier B.V. and ECNP. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Body Mass Index -
- Cognition Disorders - etiology
- Corpus Striatum - diagnostic imaging
- Corpus Striatum - drug effects
- Executive Function - drug effects
- Female -
- Frontal Lobe - diagnostic imaging
- Frontal Lobe - drug effects
- Glucagon-Like Peptide-1 Receptor - agonists
- Humans -
- Image Processing, Computer-Assisted -
- Liraglutide - therapeutic use
- Magnetic Resonance Imaging -
- Male -
- Middle Aged -
- Mood Disorders - complications
- Mood Disorders - drug therapy
- Nucleus Accumbens - diagnostic imaging
- Nucleus Accumbens - drug effects
- Outcome Assessment (Health Care) -
- Pilot Projects -
- Statistics as Topic -
- Weight Loss - drug effects
- Young Adult -
- Find related publications in this database (Keywords)
- Mood disorders
- Gtucagon-like peptide-1
- Liraglutide
- Weight loss
- Neuroimaging
- Gray matter volume